Neumora Therapeutics Common Stock Statistics
Share Statistics
Neumora Therapeutics Common Stock has 161.56M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 161.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 6.42K |
| FTD / Avg. Volume | 0.56% |
Short Selling Information
The latest short interest is 9.37M, so 5.85% of the outstanding shares have been sold short.
| Short Interest | 9.37M |
| Short % of Shares Out | 5.85% |
| Short % of Float | 17.41% |
| Short Ratio (days to cover) | 7.45 |
Valuation Ratios
The PE ratio is -11.48 and the forward PE ratio is -7.3.
| PE Ratio | -11.48 |
| Forward PE | -7.3 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 5.77 |
| P/FCF Ratio | -16.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Neumora Therapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.05, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.05 |
| Quick Ratio | 19.05 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.71 |
| Cash Flow / Debt | -48.34 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -39.72%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -39.72% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.90M |
| Employee Count | 124 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 268.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -29.57% in the last 52 weeks. The beta is 0, so Neumora Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -29.57% |
| 50-Day Moving Average | 12.2 |
| 200-Day Moving Average | 11.81 |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 1.16M |
Income Statement
In the last 12 months, Neumora Therapeutics Common Stock had revenue of $0 and earned -$235.93M in profits. Earnings per share was $-1.49.
| Revenue | 0 |
| Gross Profit | -668.00K |
| Operating Income | -188.19M |
| Net Income | -235.93M |
| EBITDA | -187.53M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.49 |
Balance Sheet
The company has $374.04M in cash and $5.23M in debt, giving a net cash position of $368.81M.
| Cash & Cash Equivalents | 374.04M |
| Total Debt | 5.23M |
| Net Cash | 368.81M |
| Retained Earnings | -703.43M |
| Total Assets | 352.54M |
| Working Capital | 316.87M |
Cash Flow
In the last 12 months, operating cash flow was -$163.28M and capital expenditures -$117.00K, giving a free cash flow of -$163.40M.
| Operating Cash Flow | -163.28M |
| Capital Expenditures | -117.00K |
| Free Cash Flow | -163.40M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.48% |
| FCF Yield | -9.83% |
Analyst Forecast
The average price target for NMRA is $23, which is 123.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 123.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 26.99 |
| Piotroski F-Score | 1 |